Literature DB >> 11477332

Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?

C H Koks1, K M Crommentuyn, R M Hoetelmans, R A Mathôt, J H Beijnen.   

Abstract

The saliva/plasma concentration ratio of fluconazole was investigated in 22 HIV-1-infected individuals with an oropharyngeal Candida infection to determine whether saliva fluconazole concentrations could provide useful information for therapeutic drug monitoring in this population. Steady-state paired plasma and saliva samples were obtained after approximately 1 week of treatment with 50-or 100-mg fluconazole as capsules. A significant correlation between plasma and salivary levels of fluconazole was observed. The median saliva/plasma concentration ratio was 1.3 and was independent of the ingested dose and the plasma fluconazole concentration. The prediction of fluconazole concentrations in plasma from the concentrations in saliva was, although unbiased, not precise. From these findings, the authors conclude that although stimulated salivary fluconazole concentrations are significantly correlated with plasma concentrations, it is not possible to predict plasma fluconazole levels from the salivary concentrations with adequate precision. However, saliva fluconazole concentrations have sufficient value to test for compliance and even semiquantitative prediction of plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477332     DOI: 10.1097/00007691-200108000-00022

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

2.  Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.

Authors:  Kim C M van der Elst; Manouche van Alst; Marjolijn N Lub-de Hooge; Kai van Hateren; Jos G W Kosterink; Jan-Willem C Alffenaar; Elisabeth H Schölvinck
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

4.  Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.

Authors:  Jeremiah D Momper; Edmund V Capparelli; Kelly C Wade; Anand Kantak; Ramasubbareddy Dhanireddy; James J Cummings; Jonathan H Nedrelow; Mark L Hudak; Gratias T Mundakel; Girija Natarajan; Jamie Gao; Matt Laughon; P Brian Smith; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.938

5.  Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.

Authors:  Hannah Yejin Kim; Anne-Grete Märtson; Erwin Dreesen; Isabel Spriet; Sebastian G Wicha; Andrew J McLachlan; Jan-Willem Alffenaar
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.